GCM
CADL icon

Ghisallo Capital Management’s Candel Therapeutics CADL Stock Holding History

Ghisallo Capital Management’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.03M Sell
100,000
-100,000
-50% -$755K 0.02% 289
2026
Q1 		$980K Buy
+200,000
New +$1.09M 0.03% 236

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Ghisallo Capital Management's CADL Position: Q2 2026 in Review

Ghisallo Capital Management reduced its Candel Therapeutics (CADL) stake by 50% in Q2 2026, selling an estimated $755K and leaving 100,000 shares worth $1.03M. The position accounts for 0.02% of the portfolio, ranked #289.

Ghisallo Capital Management first reported a position in CADL in Q1 2026 and has held it in 2 quarters since. 138 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • Ghisallo Capital Management held 100,000 shares of Candel Therapeutics worth $1.03M as of Q2 2026.
  • Ghisallo Capital Management sold 100,000 Candel Therapeutics shares in Q2 2026, an estimated $755K.
  • Candel Therapeutics made up 0.02% of Ghisallo Capital Management's portfolio in Q2 2026, its #289 holding.
  • Ghisallo Capital Management first reported a position in Candel Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 138 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on Ghisallo Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.